Table 1.
Characteristics of rivaroxaban patients
| No | Sex, age (years) |
Weight (kg) |
BMI (kg/m2) |
CLcr (ml/min) |
Hb (g/dl) |
Indication | Dosage | Duration | CHA2DS2-VASC | HAS-BLED |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M, 83 | 79 | 23.1 | 58 | 13.7 | SPAF | 20 mg OD | ≤ 1 year | 5 | 3 |
| 2 | F, 70 | N/K | N/K | N/K | 3.1 | SPAF | 15 mg OD | > 1 year | 3 | 1 |
| 3 | F, 87 | 65 | 25.7 | 48 | 6.4 | VTE | 20 mg OD | < 30 days | N/A | 2 |
| 4 | F, 67 | 80 | 24.7 | 53 | 7.2 | SPAF | 20 mg OD | > 1 year | 6 | 2 |
| 5 | F, 77 | 63 | 25.2 | 61 | 14.3 | SPAF | 15 mg OD | > 1 year | 7 | 3 |
| 6 | M, 66 | 100 | 35 | 86 | 15.6 | SPAF | 20 mg OD | ≤ 1 year | 2 | 2 |
| 7 | F, 72 | 66 | 21.6 | 46 | 12.8 | VTE | 20 mg OD | > 1 year | N/A | 3 |
| 8 | F, 90 | 70 | N/K | 60 | 13.8 | SPAF | 15 mg OD | N/K | 6 | 1 |
| 9 | F, 86 | 89 | 31.2 | 57 | 14.9 | VTE | 15 mg BID | < 30 days | N/A | 1 |
| 10 | F, 69 | 73 | 26.8 | 76 | 11.3 | VTE | 20 mg OD | > 1 year | N/A | 2 |
BID twice-daily, BMI body mass index, CLcr creatinine clearance (Cockroft-Gault equation), Hb haemoglobin, OD once-daily, N/A not applicable, N/K not known, SPAF stroke prevention in atrial fibrillation, VTE venous thromboembolism